Late Pulmonary Embolism after COVID-19 Pneumonia despite Adequate Rivaroxaban Treatment
暂无分享,去创建一个
S. Testa | G. Danzi | G. Di Tano | L. Moschini | M. Loffi
[1] Holger Moch,et al. Endothelial cell infection and endotheliitis in COVID-19 , 2020, The Lancet.
[2] S. Testa,et al. Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients , 2020, Internal and Emergency Medicine.
[3] Yutao Guo,et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up , 2020, Journal of the American College of Cardiology.
[4] J. Q. Brown,et al. Pulmonary and Cardiac Pathology in Covid-19: The First Autopsy Series from New Orleans , 2020, medRxiv.
[5] J. Thachil,et al. The versatile heparin in COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.
[6] A. Falanga,et al. ISTH interim guidance on recognition and management of coagulopathy in COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.
[7] S. Willich,et al. The management of acute venous thromboembolism in clinical practice , 2017, Thrombosis and Haemostasis.
[8] J. Beyer-Westendorf,et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. , 2014, Blood.